Parsatuzumab

Product Name: Parsatuzumab
CAS No.: 1312797-14-0
Chemical Name: Parsatuzumab
Synonyms: Parsatuzumab;Research Grade Parsatuzumab;Research Grade Parsatuzumab(DHJ76201);RG 7414|||Anti-EGFL7|||MEGF0444A|||MEGF-0444A|||RO-5490248|||M0444A
CBNumber: CB68080864
Formula Weight: 0
MOL File: Mol file

More

Less

Parsatuzumab Property

form: Liquid
color: Colorless to light yellow

More

Less

Hazard and Precautionary Statements (GHS)

More

Less

Parsatuzumab Chemical Properties,Usage,Production

Uses

Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition[1].

in vivo

Parsatuzumab (anti-EGFL7) enhances the antiangiogenesis, tumor growth control, and survival associated with antiVEGF monotherapy in several xenograft and genetically engineered murine tumor models^[1].
Parsatuzumab (50 mg/kg; i.v.; 3 times per week) targets EGFL7 and inhibits mantle cell lymphoma (MCL) cell growth and prolongs survival in mouse models of MCL^[2].

Animal Model:	NSG mice injected with Rec1 cells (s.c.)^[2]
Dosage:	50 mg/kg
Administration:	Intravenous injection; 3 times per week; sacrificed mice when tumor reached end point criteria
Result:	Significantly decreased tumor volume than IgG and increased survival of mice.

References

[1] García-Carbonero R, et al. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. Oncologist. 2017 Apr;22(4):375-e30. DOI:10.1634/theoncologist.2016-0133
[2] Chinmayee Goda, et al. Dorrance, Epidermal Growth Factor-like 7 As a Novel Therapeutic Target in Mantle Cell Lymphoma. Blood. 138(S1), 2021:3300.

Parsatuzumab Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

Parsatuzumab Suppliers

China 18 Global 18

ShangHai Biochempartner Co.,Ltd

Tel: 177-54423994 17754423994
Fax: QQ:2853530913
Email: 2853530910@QQ.com
Country: China
ProdList: 8000
Advantage: 62

Guangzhou Hongyuan Chemical Co.,Ltd

Tel: 15817493340
Email: 981810490@qq.com
Country: China
ProdList: 1566
Advantage: 58

Wuhan Chemstan Biotechnology Co., Ltd.

Tel: 027-65317797 15926423062
Fax: QQ：422450190
Email: 422450190@qq.com
Country: China
ProdList: 10308
Advantage: 58

TargetMol Chemicals Inc.

Tel: 4008200310
Email: marketing@tsbiochem.com
Country: China
ProdList: 24961
Advantage: 58

Biolab Reagents

Tel: 027-65279366 18108604356
Email: products@biolabreagent.com
Country: China
ProdList: 9868
Advantage: 58

Wuhan Jingkangen Biomedical Technology Co., Ltd

Tel: 13720134139 086-15871494362 13720134139
Email: orders@jknbiochem.com
Country: China
ProdList: 6762
Advantage: 58

Shanghai Yifei Biotechnology Co. , Ltd.

Tel: 021-65675885 18964387627
Email: customer_service@efebio.com
Country: China
ProdList: 11973
Advantage: 58

Changsha Fuzhen Biotechnology Co.，LTD

Tel: 0731-13823398 15111215862
Email: 313359644@qq.com
Country: China
ProdList: 4161
Advantage: 58

Wanxin Biotechnology (Jiaxing) Co., LTD

Tel: 0573-83568680 18057391398
Email: 3956524501@qq.com
Country: China
ProdList: 1442
Advantage: 58

Atagenix Laboratories

Tel: 027-87008169 17762441161
Email: info@atagenix.com
Country: China
ProdList: 10001
Advantage: 58

1312797-14-0, ParsatuzumabRelated Search:

Narnatumab Foralumab Sonelokimab TocilizuMab ertumaxomab citatuzumab Panobacumab Canakinumab Tisotumab Anvatabart

Parsatuzumab

Research Grade Parsatuzumab(DHJ76201)

RG 7414|||Anti-EGFL7|||MEGF0444A|||MEGF-0444A|||RO-5490248|||M0444A

Research Grade Parsatuzumab

1312797-14-0